2022-502367-37-00已完成2 期
A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Novartis Pharma Arzneimittel GmbH
Scientific
Novartis Pharma AG
研究点 (7)
Loading locations...
相似试验
已完成
1 期
A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers2023-507674-41-00Novartis Pharma AG58
招募中
1 期
A Phase 1 study of GSK5764227 in participants with advanced solid tumors2024-513663-10-01Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited112
招募中
1 期
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes in the HER2 gene)Non-small cell lung cancer2024-511246-39-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.162
尚未招募
2 期
Effect of Lu177-dotatate in meningiomaMeningioma.Malignant neoplasm of meninges, unspecifiedC70.9IRCT20190623043986N1Shiraz University of Medical Sciences10
尚未招募
不适用
177Lu-PSMA Radioligand therapy in patients with lymph node metastatic hormone-sensitive prostate cancer undergoing robot-assisted laparoscopic radical prostatectomy and extended pelvic lymph node dissectioProstate CancerNL-OMON29417To be determined10